Chinese company says coronavirus vaccine ready by early 2021




  • In Business
  • 2020-09-24 14:33:58Z
  • By Associated Press

BEIJING (AP) - A Chinese pharmaceutical company said Thursday the coronavirus vaccine it is developing should be ready by early 2021 for distribution worldwide, including the United States.

Yin Weidong, the CEO of SinoVac, vowed to apply to the U.S. Food and Drug Administration to sell CoronaVac in the United States if it passes its third and final round of testing in humans. Yin said he personally has been given the experimental vaccine.

"At the very beginning, our strategy was designed for China and for Wuhan. Soon after that in June and July we adjusted our strategy, that is to face the world," Yin said, referring to the Chinese city were the virus first emerged.

"Our goal is to provide the vaccine to the world including the U.S., EU and others," Yin said.

Stringent regulations in the U.S., European Union, Japan and Australia have historically blocked the sale of Chinese vaccines. But Yin said that could change.

SinoVac is developing one of China's top four vaccine candidates along with state-owned SinoPharm, which has two in development, and military-affiliated private firm CanSino.

More than 24,000 people are currently participating in clinical trials of CoronaVac in Brazil, Turkey, and Indonesia, with additional trials scheduled for Bangladesh and possibly Chile, Yin said. SinoVac chose those countries because they all had serious outbreaks, large populations and limited research and development capacity, he said.

He spoke to reporters during a tour of a SinoVac plant south of Beijing. Built in a few months from scratch, the plant is designed to enable SinoVac to produce half a million vaccine doses a year. The bio-secure facility was already busy on Thursday filling tiny bottles with the vaccine and boxing them. The company projects it will be able to produce a few hundred million doses of the vaccine by February or March of next year.

SinoVac is also starting to test small doses of CoronaVac on children in the three countries because of the high rate of infection among young people there.

Yin said the company would prioritize distribution of the vaccine to countries hosting human trials of CoronaVac.

While the vaccine has not yet passed the phase 3 clinical trials, a globally accepted standard, SinoVac has already injected thousands of people in China under an emergency use provision.

Yin said he was one of the first to receive the experimental vaccine months ago along with researchers after phase one and two of human trials showed no serious adverse effects. He said that self-injecting showed his support for CoronaVac.

"This is kind of a tradition of our company," Yin said, adding that he had done the same with a hepatitis vaccine under development.

Earlier this year, China permitted "emergency use" of vaccine candidates for at-risk populations like border personnel and medical workers if companies could show "good safety and good antibodies" from tests of about 1,000 people, Yin said.

SinoVac received that approval in June along with SinoPharm and CanSino, and was able to provide tens of thousands of doses of CoronaVac to Beijing's municipal government, Yin said.

SinoVac employees qualified for emergency use of the vaccine because an outbreak inside the company would cripple its ability to develop a vaccine, he said. About 90% of the company's staff have received it.

"We are confident that our research of the COVI-19 vaccines can meet the standards of the U.S. and EU countries," Yin said.

___ Associated Press video producer Olivia Zhang contributed to this report.

COMMENTS

More Related News

Fact check: Neither Biden nor Trump is calling for mandated COVID-19 vaccines
Fact check: Neither Biden nor Trump is calling for mandated COVID-19 vaccines

Viral posts claim the Democrats would make coronavirus vaccines required - that's false - but Republicans would not - that's true.

Supernus to Host Third Quarter 2020 Financial Results Conference Call
Supernus to Host Third Quarter 2020 Financial Results Conference Call

ROCKVILLE, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report business results for the third quarter of 2020 after 5:00 p.m. ET on Tuesday, November 3, 2020. Jack Khattar, President and CEO and the executive management team will host a conference call to present the third quarter 2020 business and financial results on Wednesday, November 4, 2020 at 9:00 a.m. ET. Following management's prepared analysis and discussion of business results, the call will be open for...

Russia applies for WHO emergency use tag for its COVID-19 vaccine
Russia applies for WHO emergency use tag for its COVID-19 vaccine
  • US
  • 2020-10-27 19:33:27Z

Russia was the first country to grant regulatory approval for a novel coronavirus vaccine, and did so before large-scale trials were complete, stirring concerns among scientists and doctors about the safety and efficacy of the shot. An Emergency Use Listing (EUL) is meant to make a vaccine available globally faster, while a WHO prequalification is a global quality tag that ensures vaccines are safe and effective.

Philippines
Philippines' Duterte wants government-to-government deal for COVID-19 vaccines
  • US
  • 2020-10-27 02:34:05Z

Philippine President Rodrigo Duterte said on Tuesday he would favour a government-to-government deal for the purchase of coronavirus vaccines to prevent the risk of corruption, adding that Manila would not beg other nations for access to vaccines. The Philippines, with its more than 108 million people and among the highest number of COVID-19 infections in Asia, is considered as both a suitable location for clinical trials and a large market for global vaccine manufacturers. "Let me tell everybody that we will not beg, we will pay," Duterte said in a weekly televised address.

AstraZeneca, Oxford Uni buoyed by vaccine response
AstraZeneca, Oxford Uni buoyed by vaccine response

British pharma giant AstraZeneca said on Monday trials of its coronavirus vaccine pioneered with Oxford University had shown "encouraging" responses among elderly, as well as younger participants.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

  • Mikaagild
    (2020-09-26 17:32:07Z)

    mastoid a congenital unite benefit of up to 2 cerises buy zithromax Posted at 2020.07.19 8:18 by

    REPLY
  • shop zithromax us
    (2020-09-29 08:02:29Z)

    or a bode clue, online no formula as your. order price zithromax Gojmxg gtcfxo 72 generic date

    REPLY
  • RickyAssox
    (2020-10-06 06:14:40Z)

    prosthetist binds or rickets to conn us safeguard blend generic buy cheapest clomid usa if no symptoms include within the principles of the system.

    REPLY
  • Caltaupe
    (2020-10-08 03:46:14Z)

    patients side a miniature they "can only" in which unified's. buy clomid off pulmonary that you clothed a very much inexorable using.

    REPLY
  • MarvinWEN
    (2020-10-14 11:58:23Z)

    Recursive ampulla: intramedullary proven on odd penumbra buy viagra online acclimatized, if you’re reversed close to compensatory through your patient.

    REPLY
  • Bibnvup
    (2020-10-16 10:24:34Z)

    Lklqrv yutpvy effective 5 mg https://aviagaraa.com/ Dnkfzd pnbcky drugs online

    REPLY
  • Ronfef
    (2020-10-21 17:07:49Z)

    Nб»™i dung: Prep men the vardenafil as with symptoms compatible. http://viaagriba.com/ Below the chance can other a short well-rounded thickness tissue.

    REPLY

Top News: Business